A Real World Study of Equecabtagene Autoleucel in Subjects With Relapsed and Refractory Multiple Myeloma.

Launched by PEKING UNIVERSITY PEOPLE'S HOSPITAL · Apr 15, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a treatment called Equecabtagene Autoleucel for people who have relapsed or refractory multiple myeloma, which means their cancer has come back or has not responded to previous treatments. The study aims to gather information about the characteristics of patients in China, how they are treated, and the outcomes they experience when receiving this therapy. It will include both new data collected during the study and existing data from past patients.

To be eligible for this trial, participants need to be adults diagnosed with relapsed or refractory multiple myeloma and must be approved by their doctor to receive Equecabtagene Autoleucel. They also need to agree to participate by signing a consent form. However, patients who have a severe allergy to any components of the treatment or are expected to live less than three months will not be included. If you join the study, you can expect to have regular follow-ups to monitor your health and the effects of the treatment. This trial is not yet recruiting participants, but it represents an important step in understanding how this treatment works in real-world settings.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult patients with confirmed relapsed/refractory multiple myeloma;
• • Based on clinical practice, the physician decided to administer equecabtagene autoleucel treatment;
• • Voluntarily sign the informed consent form approved by the ethics committee.
• Exclusion Criteria:
• • Patients who are hypersensitive to the active ingredients of the product or any excipients (dimethyl sulfoxide, compound electrolyte injection, human albumin);
• • The researcher believes that patients are unable to return for follow-up visits or that it is impossible to complete the study;
• • Patients with expected survival less than 3 months